文献速递心脑血管急症重症综合管理与镇静镇痛

机械心脏瓣膜患者围术期抗凝管理

Perioperative Management of Anticoagulation in Patients With Mechanical Heart Valves.
PubMed 文献 · JAMA Netw Open · 2026-09-01
一句话结论机械瓣患者VKA中断围术期30天动脉血栓栓塞风险1.5%、大出血2.1%;术后未桥接与更高ATE风险相关但需谨慎解读。

该回顾性队列研究纳入加拿大渥太华血栓门诊2016至2023年连续373例左侧机械瓣(主动脉、二尖瓣或双瓣)成人患者,共613次因计划侵入性操作中断VKA。术前治疗剂量桥接用于84.2%中断,术后用于31.5%(二尖瓣/双瓣46.0% vs 主动脉瓣23.6%)。30天ATE风险1.5%(95%CI 0.8%-2.8%),大出血2.1%(95%CI 1.2%-3.6%),临床相关出血3.9%。术后未桥接与更高ATE风险相关(4.9% vs 0.9%;sHR 5.30;95%CI 1.45-19.40;P=.01),但界标分析不再显著。

要点

  • 机械瓣患者VKA中断围术期30天ATE风险1.5%(95%CI 0.8%-2.8%),大出血风险2.1%(95%CI 1.2%-3.6%)。
  • 术后治疗剂量桥接在二尖瓣/双瓣中断中占46.0%,高于主动脉瓣的23.6%;二尖瓣/双瓣位置(aOR 2.90;95%CI 1.91-4.41)和既往血栓栓塞(aOR 1.91;95%CI 1.05-3.46)与更高术后桥接 odds 相关。
  • 术后未桥接与更高ATE风险相关(4.9% vs 0.9%;sHR 5.30;95%CI 1.45-19.40;P=.01),但界标分析不再显著(sHR 3.26;95%CI 0.62-17.21)。
  • 临床相关出血(大出血+CRNMB)发生于3.9%(95%CI 2.6%-5.8%)中断;死亡3例(0.5%;95%CI 0.2%-1.5%),其中1例死于致命性缺血性卒中。
  • 该研究为回顾性队列,不能确立术后桥接的因果保护效应;术后未桥接患者应谨慎处理,等待更强证据。

适用人群与场景

  • 排除:原文未提及。
  • 场景:血栓门诊围术期管理,非急诊/ICU院前场景。

诊断标准与关键阈值

  • 大出血和临床相关非大出血(CRNMB)按国际血栓与止血学会(ISTH)定义。
  • ATE和出血风险为术后30天评估。
  • 原文未提及VKA中断的具体阈值、桥接启动/停止阈值或评分界值。

处置流程与药物剂量

  • 原文未提及VKA中断的具体停药时间、桥接药物名称、剂量、给药途径、频次或目标值。
  • 术前治疗剂量桥接用于516次中断(84.2%),术后用于193次(31.5%)。
  • 术后桥接在二尖瓣/双瓣中断中占99/215(46.0%),主动脉瓣中断中占94/398(23.6%)。
  • 术后未桥接与更高ATE风险相关,但研究不能确立因果保护效应;原文建议对机械瓣患者省略桥接应谨慎处理。

红旗征与不能漏的情况

  • 动脉血栓栓塞(ATE):30天风险1.5%(95%CI 0.8%-2.8%),包括致命性缺血性卒中(1例死亡归因)。
  • 大出血:30天风险2.1%(95%CI 1.2%-3.6%)。
  • 临床相关出血(大出血+CRNMB):3.9%(95%CI 2.6%-5.8%)。
  • 死亡:3例(0.5%;95%CI 0.2%-1.5%),其中1例死于致命性缺血性卒中。

研究设计与关键结果

  • 研究类型:单中心回顾性队列研究;样本量373例患者、613次VKA中断;中心数1个(加拿大渥太华医院血栓门诊)。
  • 人群:左侧机械瓣(主动脉、二尖瓣或双瓣)成人,中位年龄67岁(IQR 60-73),男性217例(58.2%)。
  • 干预与对照:计划侵入性操作需中断VKA;术前治疗剂量桥接84.2%,术后31.5%;比较术后桥接与未桥接。
  • 主要终点:30天ATE风险1.5%(95%CI 0.8%-2.8%),大出血风险2.1%(95%CI 1.2%-3.6%)。
  • 关键次要终点:临床相关出血3.9%(95%CI 2.6%-5.8%);死亡0.5%(95%CI 0.2%-1.5%)。
  • 术后未桥接与更高ATE风险相关(4.9% vs 0.9%;sHR 5.30;95%CI 1.45-19.40;P=.01),界标分析不再显著(sHR 3.26;95%CI 0.62-17.21)。
  • 术后桥接的预测因素:二尖瓣/双瓣 vs 主动脉瓣(aOR 2.90;95%CI 1.91-4.41);既往血栓栓塞(aOR 1.91;95%CI 1.05-3.46)。
  • 不良事件:大出血2.1%、CRNMB纳入临床相关出血复合终点3.9%、死亡0.5%。

证据类型、等级与局限

  • 证据类型:回顾性队列研究(单中心)。
  • 证据等级或推荐强度:原文未提及。
  • 局限:回顾性设计、单中心、样本量有限、不能确立因果保护效应;术后未桥接与ATE的关联在界标分析中不再显著,需前瞻性验证。

对床旁实践的改变

  • 机械瓣患者VKA中断围术期应认识到ATE(1.5%)和大出血(2.1%)的临床有意义风险。
  • 术后治疗剂量桥接在二尖瓣/双瓣和既往血栓栓塞患者中更常见,但本研究不能证明桥接的因果保护效应。
  • 对机械瓣患者省略术后桥接应谨慎处理,尤其在高ATE风险特征(二尖瓣/双瓣位置、既往血栓栓塞)患者中,等待更强证据。
  • 不适用人群:原文未提及。
  • 常见陷阱:将术后未桥接与ATE的关联误读为因果保护效应;界标分析后关联不再显著。

指南或共识出处

  • 原文未提及指南或共识名称;研究出处为JAMA Netw Open。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Perioperative interruption of vitamin K antagonist (VKA) therapy in patients with mechanical heart valves (MHVs) is complex, and contemporary data to inform management are limited.

OBJECTIVES: To describe perioperative anticoagulation management and to estimate 30-day risks of arterial thromboembolism (ATE) and bleeding after VKA interruption in adults with left-sided MHVs.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included consecutive adult patients (aged ≥18 years) with left-sided aortic, mitral, or dual MHVs undergoing planned invasive procedures requiring VKA interruption from January 1, 2016, to December 31, 2023, with 30-day follow-up. The study was conducted at the thrombosis clinic at The Ottawa Hospital in Ontario, Canada.

EXPOSURE: Planned invasive procedure requiring temporary interruption of VKA therapy.

MAIN OUTCOMES AND MEASURES: Primary outcomes were 30-day postoperative ATE and major bleeding. Secondary outcomes included clinically relevant nonmajor bleeding (CRNMB) and all-cause mortality. Major bleeding and CRNMB were defined according to the International Society on Thrombosis and Hemostasis.

RESULTS: The cohort included 373 patients (median [IQR] age, 67 [60-73] years; 217 [58.2%] male) contributing 613 interruptions. Therapeutic-dose bridging was used preoperatively in 516 interruptions (84.2%) and postoperatively in 193 (31.5%) (99 of 215 [46.0%] in mitral or dual MHV vs 94 of 398 [23.6%] in aortic MHV interruptions). Patients with mitral or dual (vs aortic) valve position and prior thromboembolism had higher estimated odds of receiving postoperative therapeutic-dose bridging (mitral or dual vs aortic: adjusted odds ratio [aOR], 2.90; 95% CI, 1.91-4.41; prior thromboembolism: aOR, 1.91; 95% CI, 1.05-3.46). Estimated 30-day risks of ATE and major bleeding were 1.5% (95% CI, 0.8%-2.8%) and 2.1% (95% CI, 1.2%-3.6%), respectively. Clinically relevant bleeding (composite of major bleeding and CRNMB) occurred in 3.9% (95% CI, 2.6%-5.8%) of interruptions. Three deaths occurred (0.5%; 95% CI, 0.2%-1.5%), 1 attributed to fatal ischemic stroke. Omission of postoperative bridging was associated with higher estimated ATE risk (4.9% vs 0.9%; subdistribution hazard ratio [sHR], 5.30; 95% CI, 1.45-19.40; P = .01); this finding was no longer statistically significant in landmark analysis (sHR, 3.26; 95% CI, 0.62-17.21).

CONCLUSIONS AND RELEVANCE: In this retrospective cohort study, patients with MHVs experienced clinically meaningful risks of perioperative ATE and bleeding. These data do not establish a causal protective effect of postoperative bridging. However, omitting bridging in patients with MHVs was associated with a higher estimated risk of ATE in exploratory analyses and should be approached cautiously, pending stronger evidence from representative cohorts.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Hrubesz G, Chan V, Xu Y, et al. Perioperative Management of Anticoagulation in Patients With Mechanical Heart Valves. JAMA Netw Open. 2026. PMID: 42696279. doi:10.1001/jamanetworkopen.2026.32282

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。